Terms: = Ovarian cancer AND MYC, c-Myc, 4609, ENSG00000136997 AND Diagnosis
35 results:
1. Aneuploidy Landscape in Precursors of ovarian cancer.
Wang Y; Douville C; Chien YW; Wang BG; Chen CL; Pinto A; Smith SA; Drapkin R; Chui MH; Numan T; Vang R; Papadopoulos N; Wang TL; Shih IM
Clin Cancer Res; 2024 Feb; 30(3):600-615. PubMed ID: 38048050
[TBL] [Abstract] [Full Text] [Related]
2. Serial Circulating Tumor DNA Analysis with a Tumor-Naïve Next-Generation Sequencing Panel Detects Minimal Residual Disease and Predicts Outcome in ovarian cancer.
Heo J; Kim YN; Shin S; Lee K; Lee JH; Lee YJ; Choi Z; Park J; Min S; Kim SW; Choi JR; Kim S; Lee ST; Lee JY
Cancer Res; 2024 Feb; 84(3):468-478. PubMed ID: 38038965
[TBL] [Abstract] [Full Text] [Related]
3. A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors.
Bauer TM; Moore KN; Rader JS; Simpkins F; Mita AC; Beck JT; Hart L; Chu Q; Oza A; Tinker AV; Imedio ER; Kumar S; Mugundu G; Jenkins S; Chmielecki J; Jones S; Spigel D; Fu S
Target Oncol; 2023 Jul; 18(4):517-530. PubMed ID: 37278879
[TBL] [Abstract] [Full Text] [Related]
4. Classification of High-Grade Serous ovarian cancer Using Tumor Morphologic Characteristics.
Handley KF; Sims TT; Bateman NW; Glassman D; Foster KI; Lee S; Yao J; Yao H; Fellman BM; Liu J; Lu Z; Conrads KA; Hood BL; Barakat W; Zhao L; Zhang J; Westin SN; Celestino J; Rangel KM; Badal S; Pereira I; Ram PT; Maxwell GL; Eberlin LS; Futreal PA; Bast RC; Fleming ND; Conrads TP; Sood AK
JAMA Netw Open; 2022 Oct; 5(10):e2236626. PubMed ID: 36239936
[TBL] [Abstract] [Full Text] [Related]
5. NUT Carcinoma in the Pelvic Cavity With Unusual Pathologic Features.
Jung M; Kim SI; Kim JW; Jeon YK; Lee C
Int J Gynecol Pathol; 2022 May; 41(3):292-297. PubMed ID: 34166280
[TBL] [Abstract] [Full Text] [Related]
6. Trichodermin Induces G0/G1 Cell Cycle Arrest by Inhibiting c-myc in ovarian cancer Cells and Tumor Xenograft-Bearing Mice.
Gao Y; Miles SL; Dasgupta P; Rankin GO; Cutler S; Chen YC
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34065149
[TBL] [Abstract] [Full Text] [Related]
7. FrenchFISH: Poisson Models for Quantifying DNA Copy Number From Fluorescence In Situ Hybridization of Tissue Sections.
Macintyre G; Piskorz AM; Berman A; Ross E; Morse DB; Yuan K; Ennis D; Pike JA; Goranova T; McNeish IA; Brenton JD; Markowetz F
JCO Clin Cancer Inform; 2021 Feb; 5():176-186. PubMed ID: 33570999
[TBL] [Abstract] [Full Text] [Related]
8. miR-145 promotes miR-133b expression through c-myc and DNMT3A-mediated methylation in ovarian cancer cells.
Li J; Zhang S; Zou Y; Wu L; Pei M; Jiang Y
J Cell Physiol; 2020 May; 235(5):4291-4301. PubMed ID: 31612498
[TBL] [Abstract] [Full Text] [Related]
9. Circulating miRNA Profiling in Plasma Samples of ovarian cancer Patients.
Penyige A; Márton É; Soltész B; Szilágyi-Bónizs M; Póka R; Lukács J; Széles L; Nagy B
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540229
[TBL] [Abstract] [Full Text] [Related]
10. Integrating a Next Generation Sequencing Panel into Clinical Practice in ovarian cancer.
Lee YJ; Kim D; Kim HS; Na K; Lee JY; Nam EJ; Kim SW; Kim S; Kim YT
Yonsei Med J; 2019 Oct; 60(10):914-923. PubMed ID: 31538426
[TBL] [Abstract] [Full Text] [Related]
11. [ovarian Burkitt lymphoma as the primary manifestation: A case report and literature review].
Gómez Alarcón A; Quesada Fernández MN; Parras Onrubia F; Díaz Serrano MD; Quesada Villar J; Hernández Aznar JF
Medwave; 2019 Aug; 19(7):e7674. PubMed ID: 31442217
[TBL] [Abstract] [Full Text] [Related]
12. miR-145 inhibits glutamine metabolism through c-myc/GLS1 pathways in ovarian cancer cells.
Li J; Li X; Wu L; Pei M; Li H; Jiang Y
Cell Biol Int; 2019 Aug; 43(8):921-930. PubMed ID: 31115975
[TBL] [Abstract] [Full Text] [Related]
13. Using a panel of multiple tumor-associated antigens to enhance the autoantibody detection in the immunodiagnosis of ovarian cancer.
Wang P; Qin J; Ye H; Li L; Wang X; Zhang J
J Cell Biochem; 2019 Mar; 120(3):3091-3100. PubMed ID: 30484895
[TBL] [Abstract] [Full Text] [Related]
14. PRR11 Overexpression Facilitates ovarian Carcinoma Cell Proliferation, Migration, and Invasion Through Activation of the PI3K/AKT/β-Catenin Pathway.
Zhu J; Hu H; Wang J; Yang Y; Yi P
Cell Physiol Biochem; 2018; 49(2):696-705. PubMed ID: 30165366
[TBL] [Abstract] [Full Text] [Related]
15. [Non-Hodgkin´s B-lymphoma of the ovaries with an unfavourable prognosis - incidental finding during caesarean section].
Kopáčková M; Beránek P; Bydžovská I; Pytlík R; Soukup J; Mrhalová M
Ceska Gynekol; 2018; 83(1):45-49. PubMed ID: 29510639
[TBL] [Abstract] [Full Text] [Related]
16. Investigation of hypoxia networks in ovarian cancer via bioinformatics analysis.
Zhang K; Kong X; Feng G; Xiang W; Chen L; Yang F; Cao C; Ding Y; Chen H; Chu M; Wang P; Zhang B
J Ovarian Res; 2018 Feb; 11(1):16. PubMed ID: 29482638
[TBL] [Abstract] [Full Text] [Related]
17. Current treatment of double hit and double expressor lymphoma.
Reagan PM; Davies A
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):295-297. PubMed ID: 29222269
[TBL] [Abstract] [Full Text] [Related]
18. Overexpression of salusin-β is associated with poor prognosis in ovarian cancer.
Zhang Q; Chen WM; Zhang XX; Zhang HX; Wang HC; Zheng FY; Zhu FF
Oncol Rep; 2017 Mar; 37(3):1826-1832. PubMed ID: 28184918
[TBL] [Abstract] [Full Text] [Related]
19. [Expressions of ZEB2 and C-myc in epithelial ovarian cancer and their clinical significance].
Wang Q; Jiang H; Deng X; Fang W; Guo S
Nan Fang Yi Ke Da Xue Xue Bao; 2015 Dec; 35(12):1765-9. PubMed ID: 26714913
[TBL] [Abstract] [Full Text] [Related]
20. Associations between etiologic factors and mortality after endometrial cancer diagnosis: the NRG Oncology/Gynecologic Oncology Group 210 trial.
Felix AS; Scott McMeekin D; Mutch D; Walker JL; Creasman WT; Cohn DE; Ali S; Moore RG; Downs LS; Ioffe OB; Park KJ; Sherman ME; Brinton LA
Gynecol Oncol; 2015 Oct; 139(1):70-6. PubMed ID: 26341710
[TBL] [Abstract] [Full Text] [Related]
[Next]
